PHARMACODYNAMIC MARKERS INDUCED BY ALPHA INTERFERON2009125616 12/06/2006

摘要

1. A method of treating a patient with a disease or disorder mediated by interferon type I (IFN type I) or interferon alpha (IFNα), comprising: introducing an agent that binds and modulates the action of IFN type I or IFNα, wherein the patient includes an expression profile of PD markers, induced IFN type I or IFNα; and said agent neutralizes the expression profile of PD markers induced by IFN type I or IFNα in a patient. 2. The method of claim 1, further comprising detecting a neutralization of the expression profile of PD markers induced by type I IFN or IFNα in a patient. The method of claim 1, wherein the expression profile of the PD markers induced by IFN type I or IFNα includes upregulating the expression or action of the MX1, LY6E, IFI27, OAS1 IFIT1, IFI6, IFI44L, ISG15, LAMP3, OASL, RSAD2 and IFI44 genes. four. The method of claim 1, wherein the agent is a biological agent. The method of claim 4, wherein the agent is an antibody. The method of claim 5, wherein the antibody is a MEDI-545.7 antibody. The method of claim 5, wherein the antibody is specific for one or more IFN type I or IFNα subtypes, but is not a MEDI-545.8 antibody. The method of claim 1, wherein administering the agent alleviates one or more symptoms of the disease or disorder. The method of claim 5, wherein the antibody is administered at a dose of about 0.03-30 mg / kg. The method of claim 9, wherein the antibody is administered at a dose of about 0.3-3 mg / kg. The method of claim 10, wherein the antibody is administered at a dose of 0.03-1 mg / kg. The method according to one of paragraphs. 9-11, in which the agent neutralizes the expression profile of PD markers induced by type I IFN or IFNα in a patient by at least 10% .13. The method of claim 12, wherein the agent neutralizes the expression profile of PD markers induced by type I IFN or IF�